Site-directed mutagenesis of coumarin-type anticoagulant-sensitive VKORC1: evidence that highly conserved amino acids define structural requirements for enzymatic activity and inhibition by warfarin
about
Human vitamin K 2,3-epoxide reductase complex subunit 1-like 1 (VKORC1L1) mediates vitamin K-dependent intracellular antioxidant functionNovel insight into the mechanism of the vitamin K oxidoreductase (VKOR): electron relay through Cys43 and Cys51 reduces VKOR to allow vitamin K reduction and facilitation of vitamin K-dependent protein carboxylationConserved loop cysteines of vitamin K epoxide reductase complex subunit 1-like 1 (VKORC1L1) are involved in its active site regenerationStructural Modeling Insights into Human VKORC1 PhenotypesVKORC1 and VKORC1L1: Why do Vertebrates Have Two Vitamin K 2,3-Epoxide Reductases?Structure of a bacterial homologue of vitamin K epoxide reductaseStructural and functional insights into enzymes of the vitamin K cycleThe vitamin K oxidoreductase is a multimer that efficiently reduces vitamin K epoxide to hydroquinone to allow vitamin K-dependent protein carboxylationVitamin K epoxide reductase complex subunit 1 (Vkorc1) haplotype diversity in mouse priority strains.Novel mutations in the VKORC1 gene of wild rats and mice--a response to 50 years of selection pressure by warfarin?Inhibition of bacterial disulfide bond formation by the anticoagulant warfarin.Nothing in evolution makes sense except in the light of DNA.Vitamin K epoxide reductase prefers ER membrane-anchored thioredoxin-like redox partners.Purified vitamin K epoxide reductase alone is sufficient for conversion of vitamin K epoxide to vitamin K and vitamin K to vitamin KH2Mycobacterium tuberculosis vitamin K epoxide reductase homologue supports vitamin K-dependent carboxylation in mammalian cells.Transglutaminase 2-mediated activation of β-catenin signaling has a critical role in warfarin-induced vascular calcificationHuman vitamin K epoxide reductase and its bacterial homologue have different membrane topologies and reaction mechanismsBacterial species exhibit diversity in their mechanisms and capacity for protein disulfide bond formation.A cardiovascular phenotype in warfarin-resistant Vkorc1 mutant ratsVKORC1 variant genotypes influence warfarin response in patients undergoing total joint arthroplasty: a pilot studyWarfarin traps human vitamin K epoxide reductase in an intermediate state during electron transfer.Confirmation of warfarin resistance of naturally occurring VKORC1 variants by coexpression with coagulation factor IX and in silico protein modelling.Vitamin K epoxide reductase contributes to protein disulfide formation and redox homeostasis within the endoplasmic reticulum.Vitamin K epoxide reductase and its paralogous enzyme have different structures and functions.
P2860
Q24294610-79BD7841-EC8A-4FA0-994B-4313F9D2E2ADQ24304387-0CB80B94-E7C4-4892-AE04-277AED1EB80CQ24337424-58EFE40D-312A-4636-B398-09DDC364D2C4Q26796613-02314C79-2191-424C-91E7-2CC4866CB55BQ26799185-0EF3B840-D569-463A-948C-E2A8131716B1Q27659264-C9CCA59E-6A15-4099-8B97-070F86A835FFQ28086880-F89B353D-BF14-4CFE-ACC8-0F03F76A188AQ28115117-7E87C5BB-61DD-4B7B-AF14-1B4205D92005Q33388562-898AF6FA-FEF2-446C-B49E-8DB93683DD89Q33406630-2367A6F1-E74F-49C7-8050-092BC3BE41A0Q33591624-0B91BBB8-7C64-4537-9E4B-49CA8F8C1136Q33888697-CEAD19DD-C843-440B-8F5E-1E9BD4B7AA40Q34093937-17886BE1-CB6A-43E6-A84D-2C9829EE548CQ35221146-EDD24168-A5D3-46C9-A927-57F3282EE98EQ35635177-EDB0E51F-138A-434C-A746-E2B28E54EB7EQ36029304-8E8CA0FC-3E8E-47C7-9E84-EA68C5F07B77Q36298281-91921DA8-3DB0-40BA-8F94-37CB50BE2C12Q36954475-DC6DE56D-8DAC-4115-A809-3ED8DCBA875EQ37088955-07A75BD6-A588-4B68-819B-C2BDCEF493EFQ37213180-FD0F8562-CAB0-44AD-86B9-17E3A62F8C3BQ41168727-95B2B4F5-383A-4F22-8938-05BB6253802AQ41962781-F517A94D-CC2B-4E65-833A-B461C50ABEA0Q42181768-E1CF4667-2075-49B3-892D-836F84FBDAFBQ47287209-4857BB46-6252-489F-B00D-0DC90A0765E8
P2860
Site-directed mutagenesis of coumarin-type anticoagulant-sensitive VKORC1: evidence that highly conserved amino acids define structural requirements for enzymatic activity and inhibition by warfarin
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Site-directed mutagenesis of c ...... ity and inhibition by warfarin
@ast
Site-directed mutagenesis of c ...... ity and inhibition by warfarin
@en
Site-directed mutagenesis of c ...... ity and inhibition by warfarin
@en-gb
Site-directed mutagenesis of c ...... ity and inhibition by warfarin
@nl
type
label
Site-directed mutagenesis of c ...... ity and inhibition by warfarin
@ast
Site-directed mutagenesis of c ...... ity and inhibition by warfarin
@en
Site-directed mutagenesis of c ...... ity and inhibition by warfarin
@en-gb
Site-directed mutagenesis of c ...... ity and inhibition by warfarin
@nl
prefLabel
Site-directed mutagenesis of c ...... ity and inhibition by warfarin
@ast
Site-directed mutagenesis of c ...... ity and inhibition by warfarin
@en
Site-directed mutagenesis of c ...... ity and inhibition by warfarin
@en-gb
Site-directed mutagenesis of c ...... ity and inhibition by warfarin
@nl
P2093
P921
P356
P1476
Site-directed mutagenesis of c ...... ity and inhibition by warfarin
@en
P2093
Andreas Fregin
Carville G Bevans
Clemens R Müller
Johannes Oldenburg
Mirja Hünerberg
Simone Rost
P356
10.1160/TH05-02-0082
P407
P577
2005-10-01T00:00:00Z